chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Developed generalized body aches, mainly in her back and neck, and a low grade fever the evening of the day she received the vaccines. She continued to have sore throat and low grade fever,  and on 2/10/18  she felt weak and numb to the point where she was having a hard time walking. The patient did end up falling after slamming a  door, and when she went to step away, she collapsed.   Her mother took her to emergency department 2/10/2018. The ED physician felt the patient was having an inflammatory response to the vaccines she received. Seen for follow up 2/14/2018 with PCP and 1) General malaise, sore throat, cough consistent with viral syndrome. Unclear if this was already brewing before the immunizations were given. 2) Apparent reaction to vaccines with myalgias and some degree of resolving muscle weakness. Patient reports steady improvement.
pt recv vax & got sick & the next morning aches, back, neck, eyes, h/a;felt bad for 4 days then got sick 2wk p/shot;unk if r/t vax;had flu like sx, vomiting, diarrhea, aches, h/a, feeling very sick for 1wk;
Pt reported chills, fever, sweating and pain into the shoulder and through scapula.
Severe weakness 3 days after vaccine (3/5), to the point I which patient could not stand. Presented to hospital 6 days after vaccine (3/8). Hospital workup notable for CPK 45,720 U/L with CRP 109 (3/8) and low-grade fever (3/9). Negative infectious workup so far (BCx, Biofire, COVID PCR, UA without WBCs, no leukocytosis). He also had new thrombocytopenia to 84 (3/8), but possibly due to rifampin for LTBI. He remains admitted at this time, receiving fluids for rhabdo, undergoing further infectious and rheumatologic workup.
After getting covid in January 2022, I started to have panic attacks lasting several days. It happened first in January, when I had covid. Then again in June and July 2022.
Fever of greater than 101F, ranging as high as 102.6F persisted for roughly 31 hours.; This is a spontaneous report from a contactable consumer. A 28-years-old male patient started to receive second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 19Feb2021 10:00 in right arm at single dose for covid-19 immunisation. Medical history and concomitant medications were none. The patient did not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient has not been tested for COVID-19. No allergies to medications, food, or other products. Historical vaccine included first dose of BNT162B2 on 28Jan2021 12.00 PM in right arm. No vaccines within 4 weeks prior to the COVID vaccine received. The patient experienced fever of greater than 101f, ranging as high as 102.6f persisted for roughly 31 hours on 19Feb2021 21:00 with outcome of recovered.  No treatment received. Seriousness was non serious.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Pt has a rash leading from small pox vaccination (left upper arm) across the front of his shoulder and up to the base of the left side neck.
products not being mixed together before administration with no reported adverse event; receiving the liquid portion DTap-IPV and not the powder portion HIB due to the products not being mixed together before administration with no reported adverse event; Initial information received on 22-Aug-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 1 years old female patient and reported that products not being mixed together before administration with no reported adverse event and receiving the liquid portion dtap-ipv and not the powder portion hib due to the products not being mixed together before administration with no reported adverse event , for the vaccine DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE [PENTACEL (VERO)].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included HEPATITIS A VACCINE (HEPATITIS A) for Immunisation. On 18-Jul-2022, the patient received a  dose of 0.5 ml of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE , with an unknown formulation and strength , (lot: UJ622AAA ; expiry date: 07-Dec-2022) (frequency: once) via intramuscular route in the left thigh for immunization.  The clinic reported on behalf of a consumer having a medication error with PENTACEL  described as the patent only receiving the liquid portion DTap-IPV and not the powder portion HIB due to the products not being mixed together before administration with no reported adverse event (product preparation error) (single component of a two-component product administered) (onset date: 18-Jul-2022; latency: same day)   Action taken : not applicable for both the events.  Outcome: unknown for both the events   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Breakthrough case admission after 2 vaccines Moderna 3/19/21 Lot# 045A21A;  Moderna 4/16/21 Lot# 016B21A
full body rash; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (COMIRNATY), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Moderna (Dose 1, Moderna Vaxx with no AEs), for COVID-19 Immunization; Moderna (Dose 2, Moderna Vaxx with no AEs), for COVID-19 Immunization; Moderna (Dose 3, Moderna Vaxx with no AEs), for COVID-19 Immunization. The following information was reported: RASH (non-serious), outcome "unknown", described as "full body rash".  Additional information: Patient experienced full body rash after getting Covid Vaccine 2nd booster. Previously patient had received 3 doses of Moderna Vaccine with no AEs.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
varicella type rashes under her breast and spread throughout her body; Information was received from a lawyer regarding a case in litigation referring to a female patient (pt) of unknown age. Information regarding concomitant medication, current condition or historical condition was unknown. On or around 11-JUL-2014, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose number, route, batch/lot# and expiration date were unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). On an unknown date, shortly after receiving zoster vaccine live (ZOSTAVAX), the pt suffered varicella type rashes under her breast and spread throughout her body. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the pt's symptoms had resulted in physical limitations not presented prior to using zoster vaccine live (ZOSTAVAX). The pt also experienced mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the pt sustained severe and permanent personal injuries. Further, as a tragic consequence of the company's wrongful conduct, the pt suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of the company's conduct, the pt had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the event was considered as not recovered. The reporter considered varicella type rashes to be related to zoster vaccine live (ZOSTAVAX).     The event of varicella type rashes was considered as disabling.
Swelling at injection site. Has a dark discolored area on posterior left arm at the injection site (Not a bruise). Steril diluent lot: W032818. Received vaccine due to a negative varicella titer drawn for employee health.
Information has been received from a nurse concerning her 7 year old male grandson with no pertinent medical history and no drug reactions/allergies, who on an unknown date was vaccinated with a first dose of VARIVAX (Merck) as an infant. There was no concomitant medication. On 06-SEP-2008 the patient experienced chickenpox. The patient developed lesions on his buttocks, legs, neck and in his mouth. He had more lesions than his brother (WAES # 0809USA01980). The child was treated with Ibuprofen and Tylenol. He was not seen by the physician because his mother is a nurse. The patient was not able to return to school yet. There were no lab diagnostics studies performed. This is one of two sibling reports from the same source. Additional information has been requested.
got the flu, happens every time; Initial information received on 17-Dec-2022 regarding an unsolicited valid Social Media non-serious case received from patient.  This case involves an unknown age and unknown gender patient who got the flu, happens every time after receiving influenza vaccine.  The patient's past  medical treatment(s), vaccination(s) and family history were not provided. It is unknown if the patient had any medical history, concomitant disease or risk factor.  On an unknown date, the patient received a dose of suspect influenza vaccine produced by unknown manufacturer (form, strength, dose, frequency, lot number, expiry date: unknown) via unknown route in unknown administration site for Prophylactic vaccination  On an unknown date the patient got the flu, happens every time (influenza) (unknown latency) following the administration of influenza vaccine.  It is unknown if there were lab data/results available.   Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event ( got the flu, happens every time).  At time of reporting, the outcome was Unknown for the event got the flu, happens every time.
received an expired vaccine; sore arm; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (received an expired vaccine) and VACCINATION SITE PAIN (sore arm) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 076C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (received an expired vaccine) and VACCINATION SITE PAIN (sore arm). On 26-Oct-2021, EXPIRED PRODUCT ADMINISTERED (received an expired vaccine) had resolved. On 27-Oct-2021, VACCINATION SITE PAIN (sore arm) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medications were reported.   No Treatment information was reported.
On 1/4/00, the pt received the second dose of Lymerix. One hour following vax the pt experienced vague lightheadedness, left neck pain, and queasiness. The queasiness and lightheadedness persisted. The left neck pain resolved.  The most recent information received on 1/4/00, reported the condition of the pt is ongoing.
tested positive for Covid /he has mild cold-like symptoms; tested positive for Covid; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 17-year-old male patient received BNT162b2 (BNT162B2), in May2022 as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Her son (17) tested positive for COVID on 30May respectively. They are both vaccinated with Pfizer COVID vaccine. The following information was reported: DRUG INEFFECTIVE (medically significant) with onset 30May2022, outcome "unknown", described as "tested positive for Covid"; COVID-19 (medically significant) with onset 30May2022, outcome "unknown", described as "tested positive for Covid /he has mild cold-like symptoms". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (30May2022) Positive.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
18 hours extremely sore arm at site. Red and swollen at site. just did not feel well.  30 hours chills and fever 100.2 coughing spell and wheezing lasted 30 min. used old inhaler it stopped it. 42 hours noticed rash over upper abdomin. Arm still extremely sore, red and swollen at site. Fever gone
This spontaneous report was received from a Certified Medical Assistant (C.M.A.) regarding a 4 year old patient of unspecified gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 10-JUN-2016, the patient was vaccinated with improperly stored PROQUAD (lot # L050910, expiry date 14-JUN-2017) dosing regimen unknown. Call was because of a data logger. It was reported that the vaccine administered was subjected to temperature excursion of 23 degree Celsius for a time frame of 1 hour and 29 minutes. The vaccine was not subjected to any previous temperature excursion. No adverse effect was reported. Product quality complaint (PQC) was not filed. This is on of the several reports received from the same reporter. Additional information has been requested.
Adverse reaction; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 01-Feb-2021 and was forwarded to Moderna on 03-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of ADVERSE REACTION (Adverse reaction) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ADVERSE REACTION (Adverse reaction). At the time of the report, ADVERSE REACTION (Adverse reaction) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Urticaria, Cellulitis - reaction to immunization given on 5/20/10. SEPTRA 6ml BID x 10 days. BENADRYL Q 4 hours PRN.
inadvertently given expired product, with no reported adverse event; Initial information received on 10-Oct-2022 regarding an unsolicited valid non-serious case received from a healthcare professional.  This case involves a 5-year-old female patient to whom inadvertently given expired vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QIV], with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 07-Oct-2022, the patient received 0.5ml total dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (strength; standard; formulation: unknown) (lot number: UT7378MA and expiry date: 30-Jun-2022) Drug Treatment Duration: not applicable (NA)  via intramuscular route in the left deltoid for Immunization and on the same day to the patient inadvertently given expired product, with no reported adverse event (expired product administered).  This situation is reported as a medication error.  Action taken was not applicable.  At time of reporting, the outcome was Unknown.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments:  01314490:
I developed a rash consisting of many itchy red spots and patches on my front torso (upper chest to top of groin area) and some  similar but fewer spots on my back, arms, legs,  and neck.  My scalp is also itchy.  Rash began as one red spot  in the center of my chest near the breast bone and other spots began to appear.  I noticed the first spot on 1-11 or 1-12; I'm not sure of the exact date.    I scheduled an appointment with my primary care provider for 1-22 at 11:00.  He examined  me and recommended I start a course of OTC antihistamines and topical  cream (Triamcinolone Acetonide .1%) for two weeks.  The rash is a bit less itchy since starting treatment two days ago, but it is still visible and present.  The itchiness woke me from my sleep last night and the night before.
Myalgia, Fever, NauseaVomiting, malaise continued for 3 days, Day 4 felt better but "my taste was different and that lasted 2 weeks" Narrative:
ZOSTAVAX given SubQ at 1000. Pt returned 1/2 hour later with tingling mouth, chest heaviness, anxiety, diaphoresis, vomiting. Face flushed. 911 called -> to ER -> allergic reaction.
Originally reported.  Difficulty breathing.  Allergic reaction.  Severe asthma feeling.  Lasted for 3 weeks.  I have been struggling since.  My doctor and I agree that a 1nd vaccine could be life threatening.  I have worked everyday of the pandemic in healthcare.  Never testing positive once
He went through 8 days of severe chills, fever and pounding headache; He went through 8 days of severe chills, fever and pounding headache; He went through 8 days of severe chills, fever and pounding headache; This is a spontaneous report from a contactable consumer or other non healthcare professional. A male patient of an unspecified age received bnt162b2 (BNT162B2), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE NUMBER, UNKNOWN, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced that he went through 8 days of severe chills, fever and pounding headache on an unspecified date with outcome of unknown   Follow-up (24APR2021) This is a follow-up spontaneous report from a contactable consumer. This contactable male consumer(patient) reported that:Consumer said he had the 1st dose of the Pfizer-BioNTech Covid-19 Vaccine 3 weeks ago and is scheduled to receive the 2nd dose soon. After the 1st dose, he said he had headache, fever, and chills that lasted for 8 days all day. He wants to know if there have been reports of these reactions associated with the vaccine. He also wants to know what type of reactions he would have after the 2nd dose.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Fever began 8/15/03 with fatigue, body aches, and sore neck. Injection site is swollen and feels solid.
Injection site pain/soreness, redness, swelling, warmth beginning approximately 24 hours after vaccine and lasting about 7 days.  Worst symptoms were on days 2-3.
got my 2nd shot and noticing my kidney is really hurting on one side/kidney s are hurting after second shot; This spontaneous case was reported by a consumer and describes the occurrence of RENAL PAIN (got my 2nd shot and noticing my kidney is really hurting on one side/kidney s are hurting after second shot) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 2 dosage form. On an unknown date, the patient experienced RENAL PAIN (got my 2nd shot and noticing my kidney is really hurting on one side/kidney s are hurting after second shot). At the time of the report, RENAL PAIN (got my 2nd shot and noticing my kidney is really hurting on one side/kidney s are hurting after second shot) outcome was unknown.            Concomitant product use was not provided. Treatment information was not provided.
This spontaneous report was received from a registered nurse refers to a 65 year old female patient. The patient has osteopenia, dyslipidemia and sulfa gives patient a rash. On 30-APR-2013, the patient was vaccinated with a dose of 0.5 ML (milliliter) PNEUMOVAX23 (lot # reported as H01775, expiry date 04-JUL-2014). Concomitant therapies included TYELNOL, WELLBUTRIN, VALPARIN, estradiol, gabapentin, glucosamine sulfate, BONIVA, ATIVAN, METAMUCIL and Vitamins (unspecified). Approximately on 30-APR-2013 (reported as within last 24 hours at the time of this report), the patient experienced neck pain (disability) and could barely move her left arm (disability). The nurse believed that PNEUMOVAX23 was given in the shoulder joint instead of the deltoid muscle. At an unspecified time patient used NEOSPORIN (manufacturer unknown) and it caused rash. There was no treatment rendered for the events. There were no lab diagnostics performed. At the time of this report the patient had not recovered from the reported events. The patient sought medical attention (saw the physician). Additional information has been requested.
feeling very thirsty; dizziness; a rash from her neck down to her shoulder; hot & cold sensation; feeling very sluggish; This spontaneous case was reported by a consumer and describes the occurrence of THIRST (feeling very thirsty), SLUGGISHNESS (feeling very sluggish), DIZZINESS (dizziness), RASH (a rash from her neck down to her shoulder) and CHILLS (hot & cold sensation) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039a21a and 027a21a) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included MULTIVITAMIN [VITAMINS NOS], VITAMIN D [VITAMIN D NOS] and INTERFERON BETA-1A (AVONEX) for an unknown indication.   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In December 2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced SLUGGISHNESS (feeling very sluggish). On 23-Dec-2021, the patient experienced THIRST (feeling very thirsty), DIZZINESS (dizziness), RASH (a rash from her neck down to her shoulder) and CHILLS (hot & cold sensation). At the time of the report, THIRST (feeling very thirsty), SLUGGISHNESS (feeling very sluggish), DIZZINESS (dizziness), RASH (a rash from her neck down to her shoulder) and CHILLS (hot & cold sensation) outcome was unknown.            As treatment the patient was taken allergy pills and put ointment on the rash.